<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03825328</url>
  </required_header>
  <id_info>
    <org_study_id>HZ-NS/GEMOX-PC</org_study_id>
    <nct_id>NCT03825328</nct_id>
  </id_info>
  <brief_title>A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC )</brief_title>
  <official_title>A Phase II , Open-label , Investigator-initiated Trail of Sequential GEMOX/NS Chemotherapy in Patients With Untreated Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yanqiao Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harbin Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II , Open-label , Investigator-initiated Trail of Sequential GEMOX/NS
      Chemotherapy in Patients With untreated Pancreatic cancer.

      This study aims to evaluate the safety and efficacy of Sequential GEMOX/NS Chemotherapy as a
      first-line treatment of untreated Pancreatic cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 30, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>from the first drug administration up to 6 months</time_frame>
    <description>progression-free survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>from the first drug administration up to 1 year</time_frame>
    <description>overall survival</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Albumin-binding paclitaxel+S1 / gecitabine+oxaliplatin Interchanged every 2 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin-bound paclitaxel</intervention_name>
    <description>Albumin-bound paclitaxel is paclitaxel formulated as albumin-bound nanoparticles with a mean particle size of approximately 130 nanometers.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>a combination preparation of tegafur, gimeracil, and oteracil potassium</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>The compound features a square planar platinum(II) center. In contrast to cisplatin and carboplatin, oxaliplatin features the bidentate ligand 1,2-diaminocyclohexane in place of the two monodentate ammine ligands. It also features a bidentate oxalate group.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine is a synthetic pyrimidine nucleoside prodrug—a nucleoside analog in which the hydrogen atoms on the 2' carbon of deoxycytidine are replaced by fluorine atoms.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Voluntarily participate in the trial and sign the informed consent form

          2. 18 years old &lt;age &lt;75 years old

          3. Histopathological or cytologically confirmed (inoperable) locally advanced or
             recurrent metastatic pancreatic ductal adenocarcinoma with lesions measurable
             according to RECIST criteria

          4. ECOG score 0-1

          5. Life expectancy &gt; 3 months

          6. There must be a CT or MRI examination within a week

          7. at least one lesion that can be measured by the RECIST v1.1 standard

          8. No chemotherapy has been performed (the interval between postoperative adjuvant
             chemotherapy must be more than 6 months)

          9. without radiation therapy (unless there is at least one measurable target lesion in
             the non-irradiated area)

        Exclusion Criteria:

          1. pregnant or lactating women; or those who have fertility but refuse to take
             contraceptive measures;

          2. Severe active infections requiring intravenous antibiotic treatment during enrollment;

          3. those who are allergic to the test drug;

          4. There is ≥2 neuropathy (CTCAE 4.0);

          5. uncontrolled, symptomatic brain metastases or those with a history of uncontrollable
             psychiatric disorders; severe intellectual or cognitive dysfunction;

          6. Congestive heart failure, uncontrollable arrhythmia, myocardial infarction within 6
             months, unstable angina, stroke or transient ischemic attack;

          7. Have other malignant tumors within 5 years, except for fully treated cervical
             carcinoma in situ or squamous cell carcinoma of the skin, or basal cell carcinoma of
             the skin that has been basically controlled;

          8. Patients who are unable to follow the protocol or who are unable to follow up;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhang Yanqiao, PHD</last_name>
    <phone>13845120210</phone>
    <email>yanqiaozhang@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wang Guangyu, PHD</last_name>
    <phone>18249038966</phone>
    <email>18249038966@163.com</email>
  </overall_contact_backup>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2019</study_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Harbin Medical University</investigator_affiliation>
    <investigator_full_name>Yanqiao Zhang</investigator_full_name>
    <investigator_title>Director of the hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

